Opus Genetics (NASDAQ:IRD – Get Free Report) released its earnings results on Tuesday. The company reported ($0.29) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.30) by $0.01, Zacks reports. The company had revenue of $3.87 million during the quarter, compared to analyst estimates of $1.17 million. Opus Genetics had a negative return on equity of 59.72% and a negative net margin of 324.45%.
Opus Genetics Price Performance
Shares of NASDAQ IRD traded down $0.07 during trading hours on Wednesday, hitting $1.08. The company’s stock had a trading volume of 174,208 shares, compared to its average volume of 170,606. Opus Genetics has a 12 month low of $1.07 and a 12 month high of $3.40.
Wall Street Analysts Forecast Growth
Separately, HC Wainwright initiated coverage on Opus Genetics in a report on Wednesday. They set a “buy” rating and a $8.00 price objective for the company.
Opus Genetics Company Profile
Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc, formerly known as Ocuphire Pharma Inc, is based in Farmington Hills, Michigan.
Featured Stories
- Five stocks we like better than Opus Genetics
- What is a Low P/E Ratio and What Does it Tell Investors?
- Rocket Lab is the Right Stock for the Right Time
- What Is WallStreetBets and What Stocks Are They Targeting?
- SoundHound AI Will Advance By Triple Digits in 2025: Here’s Why
- What is the Shanghai Stock Exchange Composite Index?
- Celsius Holdings: Big Drop, Big Opportunity? Analysts Say Yes
Receive News & Ratings for Opus Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opus Genetics and related companies with MarketBeat.com's FREE daily email newsletter.
